Phenotype Classification and Risk Factors of Polycystic Ovary Syndrome Among Infertility Patients Treated at Subfertility Clinic, National Population and Family Development Board Malaysia
Main Article Content
Abstract
Introduction: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with rising incidence in Malaysia. The phenotype of PCOS is based on patients’ clinical and biochemical characteristics. Therefore, this study aimed to determine the phenotype classification and the main risk factor for PCOS in women attending infertility treatment at the Subfertility Clinic, National Population and Family Development Board (NPFDB). Materials and methods: This cross-sectional study was conducted among women undergoing infertility treatment at the Subfertility Clinic of NPFDB from January 2018 to December 2019. The women underwent physical examination, had their menstrual history recorded, and were diagnosed with PCOS based on Rotterdam criteria. Meanwhile, blood was taken for lipid, glucose and reproductive hormone analysis. Results: A total of 84 women who attended for infertility treatment were diagnosed with PCOS. The findings showed that the majority of PCOS women were diagnosed with PCOS phenotype D. PCOS women exhibited notable characteristics, including significantly increased body mass index (BMI), increased blood pressure, menstrual irregularities, polycystic ovaries and hirsutism. Elevated levels of luteinizing hormone (LH) and testosterone were observed in PCOS women, while follicle-stimulating hormone (FSH) and progesterone levels were significantly diminished. Moreover, PCOS women manifested lower levels of high-density lipoprotein (HDL) and increased 2-hour postprandial glucose levels compared to the control group. Interestingly, progesterone levels showed a statistically significant relationship with PCOS, whereby high progesterone levels decrease the risk of PCOS development (odds ratio [OR], 0.793; 95% confidence interval [CI], 0.638–0.987, p<0.05). Conclusion: PCOS women who came for infertility treatment in Subfertility Clinic, NPFDB were predominantly phenotype D, had low progesterone levels and presented anovulation problems with polycystic ovaries, and these characteristics are risk factors for PCOS.
Downloads
Article Details
References
Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls J Endocr Soc. 2019;3:1545–73. doi:org/10.1210/js.2019-00078.
Dashti S, Abdul Latiff L, Abdul Hamid H, Saini SM, Shah Abu Bakar A, Amirah Inani Binti Sabri, et al. Prevalence of polycystic ovary syndrome among Malaysian female university staff. Journal of Midwifery and Reproductive Health. 2019;7(1): 1560-1568. doi: 10.22038/jmrh.2018.30370.1329.
The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long term health risk related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19:41-47.
Lentscher JA, & Decherney AH. Clinical presentation and diagnosis of polycystic ovarian syndrome. Clinical obstetrics and gynecology. 2021;64(1):3-11. doi:org/10.1097/GRF.0000000000000563.
Moran LJ, Misso ML, Wild RA & Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update. 2010;16(4):347–363. doi:org/10.1093/humupd/dmq001.
Yilmaz B, Yildiz BO. Endocrinology of hirsutism: From androgens to androgen excess disorders. Frontiers of hormone research. 2019;53:108-119. doi:org/10.1159/000494907.
Lyngs J, Toft G, Hoyer BB, Guldbrandsen K, Olsen J & Ramalu H. Moderate alcohol intake and menstrual cycle characteristics. Human Reproduction. 2014;29: 351-358. doi:org/10.1093/humrep/det417.
Walker K, Decherney AH, & Saunders R. Menstrual dysfunction in PCOS. Clinical Obstetrics and Gynaecology. 2021;64(1):119-125. doi:org/10.1097/GRF.0000000000000596.
Zehravi M, Maqbool M, & Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021;33(6):333-337. doi:org/10.1515/ijamh-2021-0031.
Zeng X, Xie YJ, Liu YT, Long SL & Mo ZC. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clinica chimica acta. 2020;502:214-221. doi:org/10.1016/j.cca.2019.11.003.
Wekker V, Van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human reproduction update. 2020;26(6):942-960. doi:org/10.1093/humupd/dmaa029.
Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Frontier in Pharmacology. 2021;12:741764. doi:org/10.3389/fendo.2021.741764.
Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ & Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic– hyperinsulinaemic clamp studies. Human reproduction. 2016;31(11):2619-2631. doi:org/10.1093/humrep/dew243.
Sendur SN, & Yildiz BO. Influence of ethnicity on different aspects of polycystic ovary syndrome: a systematic review. Reproductive BioMedicine Online. 2021;42(4):799–818. doi:10.1016/j.rbmo.2020.12.006.
Espinosa ME, Sánchez R, Otzen T, Bautista-Valarezo E, Aguiar S, Corrales-Gutierrez I, Leon-Larios F, Manterola C. Phenotypic Characterization of Patients with Polycystic Ovary Syndrome in a Population from the Ecuadorian Andes: A Cross-Sectional Study. Journal of Clinical Medicine. 2024: 13(8):2376.
Zhao Y, Qiao J. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids. 2013;78:755–760. doi:org/10.1016/j.steroids.2013.04.006.
Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences. J Obstet Gynaecol Res. 2019;45(12):2330-2337. doi:10.1111/jog.14132.
Azziz R, Carmina E, Dewailly D, Diamanti‐Kandarakis E, Escobar‐Morreale HF, Futterweit W. Task Force on the Phenotypeof the Polycystic Ovary Syndrome of The Androgen E, Society P. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 2009;91:456‐88. doi:org/10.1016/j.fertnstert.2008.06.035.
Loh SF, Agarwal R, Chan JK, Chia SJ, Cho LW, Lim LH, et al. Academy of Medicine-Ministry of Health Clinical Practice Guidelines: assessment and management of infertility at primary healthcare level. Singapore Med J. 2014;55(2):58-65. doi:10.11622/smedj.2014016.
Azziz R, Kintziger K, Li R, Laven J, Morin-Papunen L, Merkin SS, Teede H, Yildiz BO. Recommendations for Epidemiologic and Phenotypic Research in Polycystic Ovary Syndrome: An Androgen Excess and PCOS Society Resource. Human Reproduction. 2019: 34: 2254–2265.
MyGovernment. 2016. Demography of population Malaysia. Department of Information, Government of Malaysia. https://www.malaysia.gov.my/portal/content/30114 Accessed 29 Julai 2023.
Zangeneh FZ, Jafarabadi M, Naghizadeh MM, Abedinia N, & Haghollahi F. Psychological distress in women with polycystic ovary syndrome from Imam Khomeini Hospital, Tehran. Journal of reproduction & infertility. 2012;13(2):111-115.
Deatsman S, Vasilopoulos T & Rhoton-Vlasak A. Age and fertility: A study on patient awareness. JBRA Assisted Reproductive. 2016;20(3):99-106.doi:10.5935/1518-0557.20160024.
Deshpande P.S. & Gupta A.S. Causes and prevalence of factors causing infertility in a public health facility. Journal of Human Reproductive Sciences. 2019;12(4):287-293. doi: 10.4103/jhrs.JHRS_140_18.
Asaldi B. Clinical Features of PCOS. Polycystic Ovarian Syndrome. 2020 doi:10.5772/intechopen.89961.
Lyngs J, Toft G, Hoyer BB, Guldbrandsen K, Olsen J & Ramalu H. Moderate alcohol intake and menstrual cycle characteristics. Human Reproduction. 2014;29:351-358. doi:org/10.1093/humrep/det417.
Hsu MI. Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clinical and experimental reproductive medicine. 2015;42(3):86. doi:10.5653/cerm.2015.42.3.86.
Techatraisak K, Wongmeerit K, Dangrat C, Wongwananuruk T, Indhavivadhana S. Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. Gynecol Endocrinol. 2016;32:276–280. doi:org/10.3109/09513590.2015.1112785.
Lim SS, Norman RJ, Davies MJ & Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity reviews. 2013;14(2):95–109. doi:org/10.1111/j.1467-789X.2012.01053.x.
Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, et al. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod. Biol. Endocrinol. 2020;18(1):1-15. doi:org/10.1186/s12958-020-00576-1.
Rajbanshi I, Sharma VK, Tuladhar ET, Bhattarai A, Raut M, Dubey RK & Niraula A. Metabolic and biochemical profile in women with polycystic ovarian syndrome attending tertiary care centre of central NEPAL. BMC Women’s Health. 2023: 23(1):208.
Badawy A, & Elnashar A. Treatment options for polycystic ovary syndrome. International Journal of Women’s Health. 2011;3:25–35. doi:10.2147/IJWH.S11304.
Ng NY, Wu H, Lau ES, Zhang X, Yang A, Tsang AY,& Ma RC. Young-onset diabetes in women with Polycystic Ovary Syndrome: A territory-wide retrospective analysis in Hong Kong. Diabetes Research and Clinical Practice, 2023:199:110640.
Celik C, Tasdemir N, Abali R, Bastu E & Yilmaz M. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: A controlled follow-up study. Fertility Sterility. 2014;101(4):1123-1128. doi:org/10.1016/j.fertnstert.2013.12.050.
Aswini R & Sabeena Jayapalan. Modified Ferrimann Gallwey score in hirsutism and its association with metabolic syndrome. International Journal of Trichology. 2017;9(1):7-13. doi: 10.4103/ijt.ijt_93_16.
Rashidi BH, Gorginzadeh M, Aalipour S, Sills ES. Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center. Archives of Endocrinology and Metabolism. 2016;60:486–491. doi:org/10.1590/2359-3997000000215.
de Medeiros SF, Yamamoto MMW, de Medeiros MAS, Barbosa BB, Soares JM & Baracat EC. Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age. Endocrine connections. 2020;9(2):74-89. doi:org/10.1530/EC-19-0496.
Haqq L, Farlane J, Dieberg G. & Smart N. Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: A systematic review and meta-analysis. Endocrine Connection. 2014;3(1):36-46. doi:org/10.1530/EC-14-0010.
Karakas S E. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clinica Chimica Acta. 2017;471:248–253. doi:org/10.1016/j.cca.2017.06.009.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova‐Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6‐15. doi:org/10.1016/j.fertnstert.2016.05.003.
Krentowska A & Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes/Metabolism Research and Reviews. 2022;38(1):e3464. doi:org/10.1002/dmrr.3464.
Khurana A, Swamy MV, Mitra S, Srinivas S, Nagaraja N. Prevalence of Polycystic Ovarian Syndrome, Phenotypes and their Ovulation Response to Sequential Letrozole Dose Escalation among Infertile Women at a Tertiary Care Centre in Southern India. J Hum Reprod Sci. 2022;15(1):42-50. doi:10.4103/jhrs.jhrs_141_21.
Elsayed AM, Al-Kaabi LS, Al-Abdulla NM, Al-Kuwari MS, Al-Mulla AA, Al-Shamari RS, et al. Clinical Phenotypes of PCOS: a Cross-Sectional Study. Reprod Sci. 2023;30(11):3261-3272. doi: 10.1007/s43032-023-01262-4.
Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, Mahboobifard F, Khalili Pouya E, Ramezani Tehrani F, et al. The prevalence of polycystic ovary syndrome, its phenotypes and cardio-metabolic features in a community sample of Iranian population: Tehran lipid and glucose study. Frontiers in Endocrinology. 2022;13:825528. doi:org/10.3389/fendo.2022.825528.
Elasam A N, Ahmed M A, Ahmed A B, Sharif M E, Abusham A, Hassan B, et al. The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. BMC Women’s Health. 2022;22(1):165. doi: 10.1186/s12905-022-01762-6.
Zeng X, Xie YJ, Liu YT, Long SL, & Mo ZC. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clinica chimica acta. 2020;502:214-221. doi:org/10.1016/j.cca.2019.11.003.
De Guevara AL, Fux-Otta C, Crisosto N, de Mereshian PS, Echiburú B, Iraci G, et al. Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. Fertility and Sterility. 2014;101(6):1732-1739. doi:org/10.1016/j.fertnstert.2014.02.020.
Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019;23(3):326-331. doi: 10.4103/ijem.IJEM_30_19.
Velija-Ašimi Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosnian Journal of basic medical sciences. 2013;13(3):180-185. doi:10.17305/bjbms.2013.2359.
Shirin S, Murray F, Goshtasebi A, Kalidasan D, Prior JC. Cyclic Progesterone Therapy in Androgenic Polycystic Ovary Syndrome (PCOS)—A 6-Month Pilot Study of a Single Woman’s Experience Changes. Medicina. 2021;57:1024. doi:org/10.3390/medicina57101024.